Disposition of 930 shares by Lyons Gary A of Neurocrine Biosciences at 42.76 subject to Rule 16b-3
| NBIX Stock | USD 136.69 3.64 2.74% |
Slightly above 67 percent of all Neurocrine Biosciences' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Neurocrine Biosciences suggests that a large number of traders are confidant. Neurocrine Biosciences' investing sentiment can be driven by a variety of factors including economic data, Neurocrine Biosciences' earnings reports, geopolitical events, and overall market trends.
Neurocrine |
Filed transaction by Neurocrine Biosciences Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Neurocrine Biosciences' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Neurocrine Biosciences' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Neurocrine Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Neurocrine Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neurocrine Biosciences Fundamental Analysis
We analyze Neurocrine Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Neurocrine Biosciences is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Neurocrine Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurocrine Biosciences stock to make a market-neutral strategy. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with similar companies.
Peers
Neurocrine Biosciences Related Equities
| EVO | Evotec SE | 2.36 | ||||
| IRWD | Ironwood Pharmaceuticals | 2.32 | ||||
| ITCI | Intracellular | 2.17 | ||||
| COLL | Collegium Pharmaceutical | 0.59 | ||||
| DVAX | Dynavax Technologies | 0.39 | ||||
| ALKS | Alkermes Plc | 0.26 | ||||
| PCRX | Pacira BioSciences, | 0.20 | ||||
| SUPN | Supernus Pharmaceuticals | 0.74 | ||||
| ANIP | ANI Pharmaceuticals | 0.94 | ||||
| AVDL | Avadel Pharmaceuticals | 1.74 | ||||
| PBH | Prestige Brand | 1.95 | ||||
| AMPH | Amphastar | 3.31 |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.